

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 016303-007120US

Assistant Commissioner for Patents
Washington, D.C. 20231

On 7-23-99



TOWNSEND and TOWNSEND and CREW LLP

By: Linda Shaffer

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

JOSHI *et al.*

Application No.: 09/295,663

Filed: April 21, 1999

For: COMBINATION THERAPY
USING NUCLEIC ACIDS AND
CONVENTIONAL DRUGS

Examiner: Not yet assigned

Art Unit: 1614

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

Box SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Notice to File Missing Parts of Application mailed May 25, 1999, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

IN THE SPECIFICATION:

On page 8, line 19, insert --(LIFDRHPIAALLCYP = SEQ ID NO:1)-- after "plasmid construct".

On page 39, line 10, insert --; SEQ ID NO:2-- after "(EALA".